medigraphic.com

2023, Número 2

Siguiente >>

Rev Hematol Mex 2023; 24 (2)


Pioneros 30 años de trasplantes de células madre hematopoyéticas en Puebla, México

Garces EJ, Olivares GJC

Idioma: Ingles.
Referencias bibliográficas: 54
Paginas: 37-45
Archivo PDF: 324.10 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenousinfusion of bone marrow in patients receiving radiationand chemotherapy. N Engl J Med 1957; 257: 491-6. doi:10.1056/NEJM195709122571102.

  2. Mathé G, Jammet H, Pendic B, Schwarzenberg L, Duplan JF,Maupin B, Latarjet R, Larrieu MJ, Kalic D, Djukic Z. Transfusionset greffes de moelle osseuse homologue chez deshumains irradies a hautes dose accidentellement. Rev FrEtudes Clin Biol 1959; 4 (3): 226-38.

  3. Dausset J. Iso-leuco-anticorps. Acta Haematol 1958; 20(1-4): 156-66. doi: 10.1159/000205478.

  4. Sosa-Sánchez R, Córdova MS, Labardini JR, Chávez-Peón F.Trasplante de médula ósea en anemia aplástica. Reportedel primer caso en México. Rev Invest Clin Mex 1980;32: 49-55.

  5. León-Rodríguez E, Sosa-Sánchez R. Trasplante de médulaósea en México. Informe del primer caso exitoso en leucemiaaguda mieloblástica. Grupo de Trasplante MedularÓseo del INNSZ. Rev Invest Clin 1992; 44 (3): 383-6.

  6. Stiff PJ, Koester AR, Weidner MK, Dvorak K, Fisher RI.Autologous bone marrow transplantation using unfractionatedcells cryopreserved in dimethylsulfoxide andhydroxyethyl starch without controlled-rate freezing. Blood1987; 70 (4): 974-8.

  7. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS,Douglas GW, Devergie A, Esperou H, Thierry D, Socie G,Lehn P, et al. Hematopoietic reconstitution in a patientwith Fanconi's anemia by means of umbilical-cord bloodfrom an HLA-identical sibling. N Engl J Med 1989; 321 (17):1174-8. doi: 10.1056/NEJM198910263211707.

  8. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D,McGrath KM, Morstyn G, Fox RM. Effect of peripheral-bloodprogenitor cells mobilised by filgrastim (G-CSF) on plateletrecovery after high-dose chemotherapy. Lancet 1992; 339(8794): 640-4. doi: 10.1016/0140-6736(92)90795-5.

  9. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW,Chabannon C, de la Camara R, Dolstra H, Duarte RF, GlassB, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP,Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N;European Society for Blood and Marrow Transplantation(EBMT). Indications for haematopoietic cell transplantationfor haematological diseases, solid tumours and immunedisorders: current practice in Europe, 2022. BoneMarrow Transplant 2022; 57 (8): 1217-1239. https://doi.org/10.1038/s41409-022-01691-w.

  10. Swart JF, Delemarre EM, van Wijk F, Boelens JJ, Kuball J, vanLaar JM, Wulffraat NM. Haematopoietic stem cell transplantationfor autoimmune diseases. Nat Rev Rheumatol 2017;13 (4): 244-256. https://doi.org/10.1038/nrrheum.2017.7.

  11. Alexander T, Greco R, Snowden JA. Hematopoietic stemcell transplantation for autoimmune disease. AnnuRev Med 2021; 72: 215-228. doi: 10.1146/annurevmed-070119-115617.

  12. Chen J, Luo L, Tian R, Yu C. A review and update for registeredclinical studies of stem cells for non-tumorous andnon-hematological diseases. Regen Ther 2021; 18: 355-362. doi: 10.1016/j.reth.2021.09.001.

  13. Gale RP, Seber A, Bonfim C, Pasquini M. Haematopoieticcell transplants in Latin America. Bone Marrow Transplant2016; 51 (7): 898-905. doi: 10.1038/bmt.2016.35.

  14. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Alemán-Hoey DD,Arizpe Bravo D, Martin-López A, Ocejo Rodríguez A. Auto-transplante en leucemia aguda de células totipotencialesmovilizadas con filgrastim [Autotransplantation in acuteleukemia using totipotent cells mobilized with filgrastim].Rev Invest Clin 1993; 45 (5): 479-80.

  15. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B,Marín-López A, Delgado-Lamas JL. Non-cryopreserved peripheralblood stem cells autotransplants for hematologicalmalignancies can be performed entirely on an outpatientbasis. Am J Hematol 1998; 58 (3): 161-4. doi: 10.1002/(sici)1096-8652(199807)58:3<161::aid-ajh1>3.0.co;2-p.

  16. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A,González-Llano O, Cantú OE, Hernández NE. Hematopoieticstem cell allografts using a non-myeloablative conditioningregimen can be safely performed on an outpatient basis:report of four cases. Bone Marrow Transplant 2000; 25 (2):131-3. doi: 10.1038/sj.bmt.1702100.

  17. Ruiz-Argüelles GJ. Allogeneic stem cell transplantationusing non-myeloablative conditioning regimens: resultsof the Mexican approach. Int J Hematol 2002; 76 Suppl 1:376-9. doi: 10.1007/BF03165287.

  18. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V,Apperley J, Slavin S, Pasquini M, Sandmaier BM, BarrettJ, Blaise D, Lowski R, Horowitz M. Defining the intensityof conditioning regimens: working definitions. Biol BloodMarrow Transplant 2009; 15 (12): 1628-33. doi: 10.1016/j.bbmt.2009.07.004.

  19. Ruiz-Argüelles GJ, Seber A, Ruiz-Delgado GJ. Conductinghematopoietic stem cell transplantation in low and middleincome countries. Hematology 2022; 27 (1): 809-812. doi:10.1080/16078454.2022.2105513.

  20. León-González M, León-Peña AA, Vallejo-Villalobos MF,Nuñez-Cortés AK, Ruiz-Argüelles A, Ruiz-Argüelles GJ.Mexican biosimilar filgrastim for autologous hematopoieticstem cell mobilization and transplantation. Rev Invest Clín2017; 68 (4): 181-3. doi: 10.1080/16078454.2022.2105513.

  21. Gómez-Almaguer D, Gómez-De León A, Colunga-PedrazaPR, Cantú-Rodríguez OG, Gutierrez-Aguirre CH, Ruíz-Arguelles G. Outpatient allogeneic hematopoietic stem-celltransplantation: a review. Ther Adv Hematol 2022; 13:20406207221080739. doi: 10.1177/20406207221080739.

  22. Gallardo-Pérez MM, Gale RP, Reyes-Cisneros OA, Sánchez-Bonilla D, Fernández-Gutiérrez JA, Stock W, MurrietaÁlvarezI, Olivares-Gazca JC, Ruiz-Delgado GJ, Fonseca R,Ruiz-Argüelles GJ. Therapy of childhood acute lymphoblasticleukemia in resource-poor geospaces. Front Oncol 2023;13: 1187268. doi: 10.3389/fonc.2023.1187268.

  23. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B,Marín-López A, Larregina-Díez A, Apreza-Molina MG.Filgrastim-mobilized peripheral-blood stem cells can bestored at 4 degrees and used in autografts to rescue highdosechemotherapy. Am J Hematol 1995; 48 (2): 100-3.https://doi.org/10.1002/ajh.2830480206.

  24. Gómez-Almaguer D, Ruiz-Argüelles GJ, Piñeiro LA, Ruiz-Argüelles A. Dos casos de trasplante heterólogo con sangreperiférica [Two cases of heterologous transplantation withperipheral blood]. Rev Invest Clin 1997; 49 (1): 41-5.

  25. Ruiz-Argüelles GJ, Gómez-Almaguer D. Making allogeneicbone marrow transplantation available to patients in developingcountries: The Mexican Experience. Open HematolJ 2008; 2 (1): 67-73. http://dx.doi.org/10.2174/1874276900802010067.

  26. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, González-Llano O,Gómez-Almaguer D. Haploidentical bone marrow transplantationin 2015 and beyond. Curr Oncol Rep 2015; 17(12): 57. doi: 10.1007/s11912-015-0482-9.

  27. González-Llano O, González-López EE, Ramírez-Cázares AC,Marcos-Ramírez ER, Ruiz-Argüelles GJ, Gómez-Almaguer D.Haploidentical peripheral blood stem cell transplantationwith posttransplant cyclophosphamide in children and adolescentswith hematological malignancies. Pediatr BloodCancer 2016; 63 (11): 2033-7. doi: 10.1002/pbc.26131.

  28. Murrieta-Álvarez I, Olivares-Gazca JC, Cantero-FortizY, León-Peña AA, Priesca-Marin JM, Ruiz-DelgadoGJ, Ruiz-Argüelles GJ. Haploidentical stem cell transplantationcan be fully conducted on an outpatientbasis. Blood 2021; 138: 4912. https://doi.org/10.1182/blood-2021-149961.

  29. Murrieta-Álvarez I, Ruiz-Argüelles GJ. Bien plus Encore:Haplos indeed can be completed on an outpatient basis.Transplant Cell Ther 2021b; 27 (6): 519-520. doi: 10.1016/j.jtct.2021.03.009.

  30. Green T, Bron D, Chomienne C, de Wit TD, de Haas F, EngertA, Hagenbeek A, Jäger U, MacIntyre E, Muckenthaler MU,Smand C, Sonneveld P. Costs of haematological diseasehigh and rising. Lancet Haematol 2016; 3 (8): e353-4. doi:10.1016/S2352-3026(16)30074-6.

  31. Weisdorf D, Ruiz-Arguelles GJ, Srivastava A, Gómez-AlmaguerD, Szer J. Economic challenges in hematopoietic celltransplantation: How will new and established programsface the growing costs? Biol Blood Marrow Transplant2017; 23 (11): 1815-1816. https://doi.org/10.1016/j.bbmt.2017.07.026.

  32. Ruiz-Argüelles GJ. Whither the bone marrow transplant?Hematology 2010; 15 (1): 1-3. doi: 10.1179/102453310X12583347009892.

  33. Schroeder T, Fenk R, Saure C, Czibere A, Bruns I, Zohren F,Haas R, Kobbe G. The Mexican way: a feasible approach toavoid DMSO toxicity. Bone Marrow Transplant 2011; 46 (3):469-71. https://doi.org/10.1038/bmt.2010.140.

  34. Ramzi M, Zakerinia M, Nourani H, Dehghani M, VojdaniR, Haghighinejad H. Non‐cryopreserved hematopoieticstem cell transplantation in multiple myeloma, a singlecenter experience. Clin Transplant 2012; 26 (1): 117-22.doi: 10.1111/j.1399-0012.2011.01432.x.

  35. Bittencourt MCB, Mariano L, Moreira F, Schmidt-Filho J, Mendrone-Jr A, Rocha V. Cryopreserved versusnon-cryopreserved peripheral blood stem cells forautologous transplantation after high-dose Melphalanin multiple myeloma: comparative analysis. Bone MarrowTransplant 2019; 54 (1): 138-141. doi: 10.1038/s41409-018-0250-1.

  36. Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E,Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, HariP, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA,Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, OthmanTB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, AdilS, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, QuessarAE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO,Novitzky N, Srivastava A, Seber A, Elsolh H, GhavamzadehA, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, NiederwieserD. Worldwide Network for Blood and MarrowTransplantation (WBMT) recommendations for establishinga hematopoietic stem cell transplantation programin countries with limited resources (Part II): Clinical,technical and socio-economic considerations. HematolOncol Stem Cell Ther 2020; 13 (1): 7-16. doi: 10.1016/j.hemonc.2019.08.002.

  37. Bekadja MA, Boumendil A, Blaise D, Chevallier P, Peggs KS,Salles G, Giebel S, Marks R, Arcese W, Milpied N, Finel H,Gorin NC. Non-cryopreserved hematopoietic stem cells inautograft patients with lymphoma: a matched-pair analysiscomparing a single center experience with the use of cryopreservedstem cells reported to the European Society forBlood and Marrow Transplantation registry. Cytotherapy2021; 23 (6): 483-487. doi: 10.1016/j.jcyt.2020.12.016.

  38. Ahmed Al-Anazi K, Alshaibani Z, Kalogianidis P. An updateon hematopoietic stem cell transplantation in patients withmultiple myeloma [Internet]. Recent updates on multiplemyeloma. IntechOpen 2023. http://dx.doi.org/10.5772/intechopen.109059.

  39. Ruiz-Argüelles GJ. Lessons learned starting a bone marrowtransplantation programme in a resource-constrainedsetting. Lancet Haematol 2020; 7 (7): e509-e510. doi:10.1016/S2352-3026(20)30184-8.

  40. Ruiz-Argüelles GJ, Gómez-Almaguer D. Lessons learnedtreating patients with multiple myeloma in resourceconstrainedsettings. Curr Hematol Malig Rep 2021; 16 (1):40-44. doi: 10.1007/s11899-021-00616-6.

  41. Ruiz-Argüelles GJ, León-Peña AA, León-González M,Nuñez-Cortes AK, Olivares-Gazca JC, Murrieta-Alvarez I,Vargas-Espinosa J, Medina-Ceballos E, Cantero-Fortiz Y,Ruiz-Argüelles A, Ruiz-Delgado MA, Ruiz-Delgado RJ, Ruiz-Reyes G, Priesca-Marín M, Torres-Priego MS, Blumenkron-Marroquin D, Ruiz-Delgado GJ. A feasibility study of thefull outpatient conduction of hematopoietic transplants inpersons with multiple sclerosis employing autologous noncryopreservedperipheral blood stem cells. Acta Haematol2017; 137 (4): 214-219. doi: 10.1159/000469655.

  42. Ruiz-Argüelles GJ, Gómez-Almaguer D. Hematopoieticstem cell transplants for persons with multiple sclerosis:Is this the best therapeutic option. Medicina Univ 2017;19: 208-9. DOI: 10.1016/j.rmu.2017.10.003

  43. Dobson R, Giovannoni G. Multiple sclerosis - a review.Eur J Neurol 2019; 26 (1): 27-40. doi: 10.1111/ene.13819.

  44. Piehl F. Current and emerging disease-modulatory therapiesand treatment targets for multiple sclerosis. J InternMed 2021; 289 (6): 771-791. doi: 10.1111/joim.13215.

  45. Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J,Graves J, Marrie RA, Montalban X, Yong VW, ThompsonAJ, Reich DS; International Advisory Committee on ClinicalTrials in Multiple Sclerosis. Multiple sclerosis progression:time for a new mechanism-driven framework.Lancet Neurol 2023; 22 (1): 78-88. doi: 10.1016/S1474-4422(22)00289-7.

  46. Ruiz-Argüelles GJ, Olivares-Gazca JC, Murrieta-ÁlvarezI, Blumenkron-Marroquin D, González-López E, Ruiz-Arguelles A, Ruiz-Delgado GJ, Gómez-De-León A, Gómez-Almaguer D. Modifications to the “Classical” autologoushematopoietic stem cell transplantation in multiplesclerosis: a less toxic approach is feasible and improvesthe neurological condition. A Mexican perspective. BiologyBlood Marrow Transplant 2018; 24 (3): S125-6. https://doi.org/10.1016/j.bbmt.2017.12.067.

  47. Ruiz-Argüelles GJ, Olivares-Gazca JC, Olivares-Gazca M,Leon-Peña AA, Murrieta-Alvarez I, Cantero-Fortiz Y, Gomez-Cruz GB, Ruiz-Argüelles A, Priesca-Marin M, Ruiz-DelgadoGJ. Self-reported changes in the expanded disabilitystatus scale score in patients with multiple sclerosis afterautologous stem cell transplants: real-world data from asingle center. Clin Exp Immunol 2019; 198 (3): 351-358.doi: 10.1111/cei.13358.

  48. Murrieta-Álvarez I, Cantero-Fortiz Y, León-Peña AA,Olivares-Gazca JC, Priesca-Marín JM, Ruiz-Delgado GJ,Gómez-De-León A, Gonzalez-Lopez EE, Jaime-Pérez JC, Gómez-Almaguer D, Ruiz-Argüelles GJ. The 1,000th transplantfor multiple sclerosis and other autoimmune disorders atthe HSCT-México program: A myriad of experiences andknowledge. Front Neurol 2021c; 12: 647425. doi: 10.3389/fneur.2021.647425.

  49. Olivares-Gazca JC, Sánchez-Bonilla D, Fernández-GutiérrezJA, Reyes-Cisneros OA, Gallardo-Pérez MM, Ruiz-DelgadoGJ, Ruiz-Argüelles GJ. Patient-reported-outcomes andsafety of autologous stem cell transplantation in multiplesclerosis: A single center experience with the Mexicanmethod in 1300 persons. Blood 2022; 140 (Supplement1): 1178-9. https://doi.org/10.1182/blood-2022-163740.

  50. Olivares-Gazca JC, Guerrero-Pesqueira F, Murrieta-AlvarezI, Cantero-Fortiz Y, León-Peña AA, Priesca-Marín JM,Gomez-Almaguer D, Gomez-De-Leon A, Ruiz-Delgado GJ,Ruiz-Argüelles GJ. Splitting the total dose of cyclophosphamidein two blocks apart during the conditioning ofautologous hematopoietic stem cell transplantation inmultiple sclerosis results in diminished cardiotoxicity:Experience in 1,000 patients. Rev Invest Clin 2022b; 74(1): 1-3. doi: 10.24875/RIC.21000206.

  51. Olivares-Gazca JC, Pastelín-Martínez MDL, Montes-Robles MA, Gallardo-Pérez MM, Hernández-Flores EJ,Robles-Nasta M, et al. Can doses of post-transplantationcyclophosphamide in haploidentical stem cell allograftsbe reduced? Hematology 2023; 28 (1): 2242176. doi:10.1080/16078454.2023.2242176.

  52. Sánchez-Bonilla D, Robles-Nasta M, Gallardo-Pérez MM,Hernández-Flores EJ, Montes-Robles M, Pastelín-MartínezML, Garcés-Eisele SJ, Olivares-Gazca JC, Ruiz-DelgadoGJ, Ruiz-Argüelles GJ. Long-term results of autograftingpersons with multiple sclerosis are better in thosenot exposed to prior disease-modifying therapies. MultScler Relat Disord 2023; 75: 104744. doi: 10.1016/j.msard.2023.104744.

  53. Gómez-Cruz GB, Olivares-Gazca M, Murrieta-Álvarez I,Olivares-Gazca JC, León-Peña A, Cantero-Fortiz Y. À-propos ofthe 1000th stem cell transplant conducted at the Clínica Ruizin Puebla. México. Rev Hematol Méx 2019; 20 (2): 150-83.

  54. Maziarz RT. Letter to the editor. Rev Hematol Mex 2020;21 (1): 71.




2020     |     www.medigraphic.com